Advanced

Gene expression profilers and conventional clinical markers to predict distant recurrences for premenopausal breast cancer patients after adjuvant chemotherapy.

Niméus, Emma LU ; Ritz, Cecilia LU ; Edén, Patrik LU ; Johnsson, Anders LU ; Ohlsson, Mattias LU ; Forsare, Carina LU ; Östberg, Gorel ; Fernö, Mårten LU and Peterson, Carsten LU (2006) In European Journal of Cancer 42(16). p.2729-2737
Abstract
A large proportion of breast cancer patients are treated with adjuvant chemotherapy after the primary operation, but some will recur in spite of this treatment. In order to achieve an improved and more individualised therapy, our knowledge in mechanisms for drug resistance needs to be increased. We have investigated to what extent cDNA microarray measurements could distinguish the likelihood of recurrences after adjuvant CMF (cyclophosphamide, methotrexate and 5-fluorouracil) treatment of premenopausal, lymph node positive breast cancer patients, and have also compared this with the corresponding performance when using conventional clinical variables. We tried several gene selection strategies, and built classifiers using the resulting... (More)
A large proportion of breast cancer patients are treated with adjuvant chemotherapy after the primary operation, but some will recur in spite of this treatment. In order to achieve an improved and more individualised therapy, our knowledge in mechanisms for drug resistance needs to be increased. We have investigated to what extent cDNA microarray measurements could distinguish the likelihood of recurrences after adjuvant CMF (cyclophosphamide, methotrexate and 5-fluorouracil) treatment of premenopausal, lymph node positive breast cancer patients, and have also compared this with the corresponding performance when using conventional clinical variables. We tried several gene selection strategies, and built classifiers using the resulting gene lists. The best performing classifier with odds ratio (OR) = 6.5 (95% confidence interval (CI) = 1.4-62) did not outperform corresponding classifiers based on clinical variables. For the clinical variables, calibrated on the samples, either using all the clinical parameters or the Nottingham Prognostic Index (NPI) parameters, the areas under the receiver operating characteristics (ROC) curve were 0.78 and 0.79, respectively. The ORs at 90% sensitivity were 15 (95% CI = 3.1-140) and 10 (95% CI = 2.1-97), respectively. Our data have provided evidence for a comparable prediction of clinical outcome in CMF-treated breast cancer patients using conventional clinical variables and gene expression based markers. (c) 2006 Elsevier Ltd. All rights reserved. (Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
drug resistance, breast cancer, prognostic markers, cDNA microarray
in
European Journal of Cancer
volume
42
issue
16
pages
2729 - 2737
publisher
Elsevier
external identifiers
  • wos:000242501700020
  • scopus:33750082390
ISSN
1879-0852
DOI
10.1016/j.ejca.2006.06.031
language
English
LU publication?
yes
id
7ea23511-af20-4f61-a047-4d636a3c99c7 (old id 162446)
alternative location
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17023159&dopt=Abstract
date added to LUP
2016-04-01 12:03:51
date last changed
2020-01-12 09:08:22
@article{7ea23511-af20-4f61-a047-4d636a3c99c7,
  abstract     = {A large proportion of breast cancer patients are treated with adjuvant chemotherapy after the primary operation, but some will recur in spite of this treatment. In order to achieve an improved and more individualised therapy, our knowledge in mechanisms for drug resistance needs to be increased. We have investigated to what extent cDNA microarray measurements could distinguish the likelihood of recurrences after adjuvant CMF (cyclophosphamide, methotrexate and 5-fluorouracil) treatment of premenopausal, lymph node positive breast cancer patients, and have also compared this with the corresponding performance when using conventional clinical variables. We tried several gene selection strategies, and built classifiers using the resulting gene lists. The best performing classifier with odds ratio (OR) = 6.5 (95% confidence interval (CI) = 1.4-62) did not outperform corresponding classifiers based on clinical variables. For the clinical variables, calibrated on the samples, either using all the clinical parameters or the Nottingham Prognostic Index (NPI) parameters, the areas under the receiver operating characteristics (ROC) curve were 0.78 and 0.79, respectively. The ORs at 90% sensitivity were 15 (95% CI = 3.1-140) and 10 (95% CI = 2.1-97), respectively. Our data have provided evidence for a comparable prediction of clinical outcome in CMF-treated breast cancer patients using conventional clinical variables and gene expression based markers. (c) 2006 Elsevier Ltd. All rights reserved.},
  author       = {Niméus, Emma and Ritz, Cecilia and Edén, Patrik and Johnsson, Anders and Ohlsson, Mattias and Forsare, Carina and Östberg, Gorel and Fernö, Mårten and Peterson, Carsten},
  issn         = {1879-0852},
  language     = {eng},
  number       = {16},
  pages        = {2729--2737},
  publisher    = {Elsevier},
  series       = {European Journal of Cancer},
  title        = {Gene expression profilers and conventional clinical markers to predict distant recurrences for premenopausal breast cancer patients after adjuvant chemotherapy.},
  url          = {https://lup.lub.lu.se/search/ws/files/2765776/625702.pdf},
  doi          = {10.1016/j.ejca.2006.06.031},
  volume       = {42},
  year         = {2006},
}